SB-431542 | CAS#301836-41-9 | TGF-beta receptor inhibitor

MedKoo Cat#: 401910 | Name: SB-431542

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB-431542 is a novel small molecule inhibitor of the type I TGF-beta receptor, on a panel of human malignant glioma cell lines. SB-431542 blocked the phosphorylation and nuclear translocation of the SMADs, intracellular mediators of TGF-beta signaling, with decreased TGF-beta-mediated transcription. Furthermore, SB-431542 inhibited the expression of two critical effectors of TGF-beta-vascular endothelial growth factor and plasminogen activator inhibitor-1.

Chemical Structure

SB-431542

CAS#301836-41-9

Theoretical Analysis

MedKoo Cat#: 401910

Name: SB-431542

CAS#: 301836-41-9

Chemical Formula: C22H16N4O3

Exact Mass: 384.1222

Molecular Weight: 384.39

Elemental Analysis: C, 68.74; H, 4.20; N, 14.58; O, 12.49

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 150.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,650.00	Ready to ship
1g	USD 2,950.00	Ready to ship
2g	USD 5,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SB431542; SB-431542; SB 431542

IUPAC/Chemical Name

4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide

InChi Key

FHYUGAJXYORMHI-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)

SMILES Code

O=C(N)C1=CC=C(C2=NC(C3=CC=C(OCO4)C4=C3)=C(C5=NC=CC=C5)N2)C=C1

Appearance

white to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#TZC70419

QC Data

View QC data: current batch, Lot#TZC70419

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SB-431542 is an inhibitor of ALK5/TGF-β type I Receptor with an IC50 value of 94 nM.

In vitro activity:

This study showed that the exposure of iPSCs and ESCs to SB431542 promotes the differentiation of these pluripotent stem cells to cells with characteristics that closely resemble those of hMSCs. In the absence of SB431542, undifferentiated iPSCs and ESCs cultured on Geltrex in complete E8 medium appeared as circular and flat colonies with a well-defined border. As expected, these cells lacked expression of the mesenchymal stem cell markers CD29 and CD44 and expressed high levels of the pluripotent stem cell markers Tra 1-60, Oct-4, SSEA-3, CD90, CD9, and HSP90β. Reference: Stem Cells Int. 2018; 2018: 7878201. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051046/

In vivo activity:

This study performed a fluorescent modified-TUNEL assay on injured muscle from PDGFRα-GFP reporter mice (N = 3/group) to assess for apoptotic cells. This study observed an increase in number of apoptotic cells in injured muscle of mice treated with SB431542 compared to vehicle (Fig 7C and 7D), with an FAP cell apoptotic index of 8.3 ± 1.4% in the injured muscle of mice treated with SB431542 compared to 3.0 ± 0.8% in the vehicle group (Fig 7E, p<0.05). There was no significant difference in apoptotic index of the sham-side muscle of both groups, with indices of 8.5 ± 2.1% and 10.9 ± 4.6% in the treatment and vehicle groups, respectively (Fig 7A and 7B). Reference: PLoS One. 2016; 11(5): e0155486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871364/

	Solvent	mg/mL	mM
Solubility
	DMSO	51.8	134.78
	Ethanol	8.0	62.46

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 384.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Leyendecker Junior A. TGF-β Inhibitor SB431542 Promotes the Differentiation of Induced Pluripotent Stem Cells and Embryonic Stem Cells into Mesenchymal-Like Cells. Stem Cells Int. 2018 Jul 2;2018:7878201. doi: 10.1155/2018/7878201. PMID: 30057627; PMCID: PMC6051046. 2. Liao K, Yong CW, Hua K. SB431542 inhibited cigarette smoke extract induced invasiveness of A549 cells via the TGF-β1/Smad2/MMP3 pathway. Oncol Lett. 2018 Jun;15(6):9681-9686. doi: 10.3892/ol.2018.8556. Epub 2018 Apr 23. PMID: 29963124; PMCID: PMC6020173. 3. Xu J, Liu J, Gan Y, Dai K, Zhao J, Huang M, Huang Y, Zhuang Y, Zhang X. High-Dose TGF-β1 Impairs Mesenchymal Stem Cell-Mediated Bone Regeneration via Bmp2 Inhibition. J Bone Miner Res. 2020 Jan;35(1):167-180. doi: 10.1002/jbmr.3871. Epub 2019 Oct 22. PMID: 31487395. 4. Davies MR, Liu X, Lee L, Laron D, Ning AY, Kim HT, Feeley BT. TGF-β Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro/Adipogenic Progenitor Apoptosis. PLoS One. 2016 May 17;11(5):e0155486. doi: 10.1371/journal.pone.0155486. PMID: 27186977; PMCID: PMC4871364.

In vitro protocol:

In vivo protocol:

1. Xu J, Liu J, Gan Y, Dai K, Zhao J, Huang M, Huang Y, Zhuang Y, Zhang X. High-Dose TGF-β1 Impairs Mesenchymal Stem Cell-Mediated Bone Regeneration via Bmp2 Inhibition. J Bone Miner Res. 2020 Jan;35(1):167-180. doi: 10.1002/jbmr.3871. Epub 2019 Oct 22. PMID: 31487395. 2. Davies MR, Liu X, Lee L, Laron D, Ning AY, Kim HT, Feeley BT. TGF-β Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro/Adipogenic Progenitor Apoptosis. PLoS One. 2016 May 17;11(5):e0155486. doi: 10.1371/journal.pone.0155486. PMID: 27186977; PMCID: PMC4871364.

1: Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002 Jul;62(1):65-74. doi: 10.1124/mol.62.1.65. PMID: 12065756. 2: Xiao YQ, Liu K, Shen JF, Xu GT, Ye W. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1698-706. doi: 10.1167/iovs.08-1675. Epub 2008 Dec 20. PMID: 19098325. 3: Lee AJ, Mahoney CM, Cai CC, Ichinose R, Stefani RM, Marra KG, Ateshian GA, Shah RP, Vunjak-Novakovic G, Hung CT. Sustained Delivery of SB-431542, a Type I Transforming Growth Factor Beta-1 Receptor Inhibitor, to Prevent Arthrofibrosis. Tissue Eng Part A. 2021 Nov;27(21-22):1411-1421. doi: 10.1089/ten.TEA.2021.0029. Epub 2021 May 12. PMID: 33752445; PMCID: PMC8827116. 4: Hasegawa T, Nakao A, Sumiyoshi K, Tsuchihashi H, Ogawa H. SB-431542 inhibits TGF-beta-induced contraction of collagen gel by normal and keloid fibroblasts. J Dermatol Sci. 2005 Jul;39(1):33-8. doi: 10.1016/j.jdermsci.2005.01.013. PMID: 15978417. 5: Atis M, Akcan U, Altunsu D, Ayvaz E, Uğur Yılmaz C, Sarıkaya D, Temizyürek A, Ahıshalı B, Girouard H, Kaya M. Targeting the blood-brain barrier disruption in hypertension by ALK5/TGF-Β type I receptor inhibitor SB-431542 and dynamin inhibitor dynasore. Brain Res. 2022 Nov 1;1794:148071. doi: 10.1016/j.brainres.2022.148071. Epub 2022 Sep 1. PMID: 36058283. 6: Teplitsky JE, Vinokurtseva A, Armstrong JJ, Denstedt J, Liu H, Hutnik CML. ALK5 Inhibition of Subconjunctival Scarring From Glaucoma Surgery: Effects of SB-431542 Compared to Mitomycin C in Human Tenon's Capsule Fibroblasts. Transl Vis Sci Technol. 2023 Feb 1;12(2):31. doi: 10.1167/tvst.12.2.31. PMID: 36826843; PMCID: PMC9973532. 7: Yuan W, Liu W, Cai H, Sun X, Yang D, Xu F, Jin C. SB-431542, a specific inhibitor of the TGF-β type I receptor inhibits hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie. 2016 Feb;71(2):94-100. PMID: 27004374. 8: Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, Kubo N, Ohira M, Hirakawa K. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 2010 Dec;24(6):1637-43. doi: 10.3892/or_00001028. PMID: 21042762. 9: Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun;3(6):737-45. PMID: 15210860. 10: Waghabi MC, Keramidas M, Calvet CM, Meuser M, de Nazaré C Soeiro M, Mendonça-Lima L, Araújo-Jorge TC, Feige JJ, Bailly S. SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob Agents Chemother. 2007 Aug;51(8):2905-10. doi: 10.1128/AAC.00022-07. Epub 2007 May 25. PMID: 17526757; PMCID: PMC1932517. 11: Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, Miyazawa K. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 2003 Nov 15;63(22):7791-8. PMID: 14633705. 12: Yu Y, Liang Y, Xie F, Zhang Z, Zhang P, Zhao X, Zhang Z, Liang Z, Li D, Wang L, Chen Y, Sun L, Niu H, Wang Y. Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation. Cancer Lett. 2024 Jul 1;593:216964. doi: 10.1016/j.canlet.2024.216964. Epub 2024 May 16. PMID: 38762193. 13: Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002 Jul;62(1):58-64. doi: 10.1124/mol.62.1.58. PMID: 12065755. 14: Mahmood A, Harkness L, Schrøder HD, Abdallah BM, Kassem M. Enhanced differentiation of human embryonic stem cells to mesenchymal progenitors by inhibition of TGF-beta/activin/nodal signaling using SB-431542. J Bone Miner Res. 2010 Jun;25(6):1216-33. doi: 10.1002/jbmr.34. PMID: 20200949. 15: Muppala S, Xiao R, Krukovets I, Verbovetsky D, Yendamuri R, Habib N, Raman P, Plow E, Stenina-Adognravi O. Thrombospondin-4 mediates TGF-β-induced angiogenesis. Oncogene. 2017 Sep 7;36(36):5189-5198. doi: 10.1038/onc.2017.140. Epub 2017 May 8. PMID: 28481870; PMCID: PMC5589494. 16: Xu Y, Liu H, Xiong W, Peng Y, Li X, Long X, Jin J, Liang J, Weng R, Liu J, Zhang L, Liu Y. A novel mechanism regulating pyroptosis-induced fibrosis in endometriosis via lnc-MALAT1/miR-141-3p/NLRP3 pathway†. Biol Reprod. 2023 Aug 10;109(2):156-171. doi: 10.1093/biolre/ioad057. PMID: 37233993. 17: Ge J, Ge J, Tang G, Xiong D, Zhu D, Ding X, Zhou X, Sang M. Machine learning-based identification of biomarkers and drugs in immunologically cold and hot pancreatic adenocarcinomas. J Transl Med. 2024 Aug 16;22(1):775. doi: 10.1186/s12967-024-05590-0. PMID: 39152432; PMCID: PMC11328457. 18: Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May;7(5):509-21. doi: 10.1593/neo.04640. PMID: 15967103; PMCID: PMC1501161. 19: Tang BL, Liu Y, Zhang JL, Lu ML, Wang HX. Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to- mesenchymal transition and inflammation by regulating CCN1. Biomed Pharmacother. 2023 Aug;164:114920. doi: 10.1016/j.biopha.2023.114920. Epub 2023 May 20. PMID: 37216706. 20: Tschernia NP, Gulley JL. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy. BioDrugs. 2022 Mar;36(2):153-180. doi: 10.1007/s40259-022-00521-1. Epub 2022 Mar 30. PMID: 35353346; PMCID: PMC8986721.